Morepen Laboratories Limited
MOREPENLAB · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹55.02.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%7.9%
- ✓Low debt (D/E < 0.5)0.17x
- ✕Positive free cash flow
- ✕Revenue growth > 10%4%
- ✕Earnings growing-19%
- ✕Net margin ≥ 10%5.3%
- ✓Current ratio > 1.52.37
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 3.49
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 3.49.
Weaknesses
- •Low return on equity (7.9%).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Trades ~32% below our estimated fair value.
Threats
- •Earnings contracting year on year.
About Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose te
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.